Publications by authors named "Ruifang An"

Human papillomavirus (HPV) screening is crucial for the diagnosis of cervical cancer. In this study, we have combined photoactivated CRISPR-Cas12a with tube-in-tube structure and recombinase polymerase amplification (RPA) to enable simple, rapid and convenient visualization detection of HPV16, facilitated by blue UV light at 302 nm. It serves as a potential tool for on-site diagnostic use, which could be beneficial in terms of portability and speed.

View Article and Find Full Text PDF

Background: It remains unclear whether adding CTLA-4 blockade to PD-1/PD-L1 blockade improves clinical outcomes in cervical cancer (CC).

Methods: In this randomized, double-blind, placebo-controlled, phase 2 study (ClinicalTrials.gov: NCT04590599), patients with recurrent/metastatic CC (R/M CC) who experienced disease progression after or during platinum-based chemotherapy were enrolled from 37 centers across China and randomly assigned (1:1), stratified by PD-L1 expression and prior treatment lines, to receive either IBI310 plus sintilimab or placebo plus sintilimab intravenously every 3 weeks for 12 weeks, followed by sintilimab alone.

View Article and Find Full Text PDF

The prevalence of sperm DNA fragmentation (SDF) is significantly higher in males with infertility, which is often associated with oligozoospermia and hypospermia. It can also occur in patients with infertility who have normal conventional semen indicators. The etiologies involve aberrations in sperm maturation, dysregulated apoptotic processes, and heightened levels of oxidative stress.

View Article and Find Full Text PDF

Background: Ovarian cancer is a type of gynecological cancer with extremely high fatality rate. Ferroptosis, an iron-dependent regulated cell death, inhibits the immune infiltration of tumor cells. Therefore, it is worthwhile to explore the effects of ferroptosis-related gene signatures and immune infiltration patterns on the clinical prognosis of ovarian cancer.

View Article and Find Full Text PDF

The aim of this study is to identify differentially expressed proteins (DEPs) in granulose cells (GCs) from women with or withoutpolycystic ovary syndrome (PCOS) via data independent acquisition (DIA) proteomic analysis.A total of 63 women were recruited for this study, 34 PCOS patients as experimental group (P), and 29 women without PCOS as Normal group (NP). DIA-based proteomic analysis was performed to identify DEPs in GCs between the P and NP samples.

View Article and Find Full Text PDF
Article Synopsis
  • Platinum-resistant ovarian cancer is a severe and deadly gynecological disease with few effective treatment options, and chiauranib is a new drug that targets multiple pathways to help treat it.
  • A phase II study assessed chiauranib combined with either etoposide or weekly-paclitaxel chemotherapy in Chinese patients with recurrent ovarian cancer, focusing on progression-free survival (PFS) as the main outcome.
  • The results showed that patients receiving the combination treatment had improved PFS (about 5.4-5.6 months), indicating that chiauranib may be a promising option in treating this type of cancer, leading to plans for further studies.
View Article and Find Full Text PDF

Background: Patients with choriocarcinoma (CC) accompanying chemoresistance conventionally present a poor prognosis. Whether ras protein activator like-1 (RASAL1) functions as a tumor promoter or suppressor depends on tumor types. However, the role of RASAL1 in process of chemoresistance of CC and underlying molecular mechanism remain elusive.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated the effectiveness and safety of combining bevacizumab with carboplatin and paclitaxel (CP) as a first-line treatment for stage III/IV ovarian cancer in Chinese patients after surgery.
  • Results showed that patients receiving bevacizumab + CP had a median progression-free survival (PFS) of 22.6 months, significantly longer than the 12.3 months for those on placebo + CP.
  • The safety profile indicated that treatment-related severe side effects were more common in the bevacizumab group (94%) compared to the placebo group (68%), but the drug's overall safety was consistent with previous findings.
View Article and Find Full Text PDF

Background: The prospective phase III multi-centre L-MOCA trial (NCT03534453) has demonstrated the encouraging efficacy and manageable safety profile of olaparib maintenance therapy in the Asian (mainly Chinese) patients with platinum-sensitive relapsed ovarian cancer (PSROC). In this study, we report the preplanned exploratory biomarker analysis of the L-MOCA trial, which investigated the effects of homologous recombination deficiency (HRD) and programmed cell death ligand 1 (PD-L1) expression on olaparib efficacy.

Methods: HRD status was determined using the ACTHRD assay, an enrichment-based targeted next-generation sequencing assay.

View Article and Find Full Text PDF

Background: Niraparib significantly prolonged progression-free survival versus placebo in patients with platinum-sensitive, recurrent ovarian cancer (PSROC), regardless of germline mutation (gm) status, in NORA. This analysis reports final data on overall survival (OS).

Methods: This randomised, double-blind, placebo-controlled, phase 3 trial enrolled patients across 30 centres in China between 26 September 2017 and 2 February 2019 (clinicaltrials.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on improving outcomes for patients with platinum-resistant, recurrent ovarian cancer by testing a biomarker-driven combination of therapies including PARP inhibitors, immune checkpoint inhibitors, and chemotherapy.
  • The BRIGHT Trial is a phase II study that plans to enroll 160 patients from 11 centers in China, assigning them to three experimental treatment arms based on specific genomic and immunologic markers.
  • Patient treatment will continue until their disease progresses or they experience severe side effects, with a thorough documentation of any adverse events throughout the study.
View Article and Find Full Text PDF

Objective: QL1604 is a highly selective, humanized monoclonal antibody against programmed death protein 1. We assessed the efficacy and safety of QL1604 plus chemotherapy as first-line treatment in patients with advanced cervical cancer.

Methods: This was a multicenter, open-label, single-arm, phase II study.

View Article and Find Full Text PDF

Purpose: To evaluate the efficacy and safety of oral ibrexafungerp (HS-10366) versus placebo in Chinese patients with vulvovaginal candidiasis (VVC).

Methods: A double-blind, placebo-controlled, randomized, multicenter phase III study was conducted in symptomatic VVC patients. Patients received (2:1) twice-daily oral ibrexafungerp 300 mg or matching placebo for 1 day.

View Article and Find Full Text PDF

Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been reported to play a diagnostic and predictive role in gestational trophoblastic disease. However, the conclusions are still ambiguous. This meta-analysis aimed to evaluate the combined predictive value of NLR and PLR in the malignant progression of gestational trophoblastic disease.

View Article and Find Full Text PDF

Introduction: Gestational trophoblastic neoplasia (GTN) is a highly invasive tumor, mainly spreading to the lungs. However, lung metastasis in GTN is usually not considered as an adverse prognostic factor. Therefore, the aim of this study was to summarize the results of previous studies and evaluate the effects of lung metastasis on the treatment and prognosis of GTN.

View Article and Find Full Text PDF

Choriocarcinoma can be cured by chemotherapy, but this causes resistance and severe side effects that bring about physical and psychological consequences for patients. Therefore, there is still an urgent need to find other alternative minimally invasive therapies to halt the progression of choriocarcinoma. Novel carbon-coated selenium nanoparticles (C-Se) were successfully synthesized for choriocarcinoma photothermal therapy.

View Article and Find Full Text PDF
Article Synopsis
  • Immune checkpoint inhibitors like PD-1 and CTLA-4 have shown effectiveness in treating various cancers, prompting the study of cadonilimab, a bispecific antibody for patients with advanced solid tumors.
  • This multicenter trial in China included patients with specific eligibility criteria, assessing cadonilimab's safety and effectiveness through different dosage phases across cancers like cervical, esophageal, and liver cancer.
  • The primary focus was on determining safety during phase 1b and the objective response rate in phase 2, with results being documented and registered under ClinicalTrial.gov, indicating the study has concluded.
View Article and Find Full Text PDF

The aim of this study was to explore risk factors of recurrent bacterial vaginosis (RBV) among women of reproductive age. This cross-sectional study was carried out in real-world conditions. Women with RBV were selected, and simultaneously uncomplicated bacterial vaginosis (UBV) and those who underwent routine gynecological examination and had normal vaginal microflora were also recruited as the control.

View Article and Find Full Text PDF

Ovarian cancer (OC), is a tumor that poses a serious threat to women's health due to its high mortality rate and bleak prognosis. Pyroptosis, a type of programmed cell death, is important for determining the prognosis of a patient's prognosis for cancer and may represent a novel target for treatment. However, research into how prognosis is impacted by pyroptosis-related genes (PRGs) is poorly understood.

View Article and Find Full Text PDF
Article Synopsis
  • The study analyzed clinical features and demographics of gestational trophoblastic neoplasia (GTN) patients, focusing on choriocarcinoma (CC), placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT).
  • Data was gathered from a local hospital and the SEER database, covering cases from 1975 to 2022, with significant findings related to surgery, age, FIGO stage, and other risk factors that influence prognosis for CC patients.
  • The study highlights the importance of multidisciplinary care for CC patients, especially those facing psychological challenges associated with unfavorable factors like marital status and unemployment.
View Article and Find Full Text PDF

Background: Vaginal microecology has a definite influence on human papillomavirus (HPV) infection and clearance, but the specific correlation is still controversial. This research aimed to investigate the differences in the vaginal microenvironment of different types of HPV infection and also provide data supporting clinical diagnosis and treatment.

Methods: According to strict inclusion and exclusion criteria, the case data of 2,358 female patients who underwent vaginal microecology and HPV-DNA tests at the same time in the Department of Obstetrics and Gynecology of the First Affiliated Hospital of Xi'an Jiaotong University from May 2021 to March 2022 were retrospectively analyzed.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on the effectiveness and safety of serplulimab combined with nab-paclitaxel in patients with advanced cervical cancer expressing PD-L1.
  • In a phase II trial, 21 patients were treated and showed a promising objective response rate of 57.1%, with some achieving complete and partial responses.
  • While there were notable adverse events (81.0% had severe treatment-related issues), the combination therapy demonstrated significant clinical activity and a tolerable safety profile.
View Article and Find Full Text PDF

This study was conducted to illustrate the origin of these PE-related ncRNAs in maternal circulation and their underlying transport methods into target cells. We selected 10 women with severe pre-eclampsia (PE group) and 10 healthy participants who served as controls (NC group). Exosomes were isolated from their sera and their origin was determined by a specific marker, placental alkaline phosphatase (PLAP).

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_session5h0nd69jlagnjuuplmvu224o3auig2b4): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once